Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
75%(6 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_4
1
11%
Ph phase_1
2
22%
Ph phase_3
1
11%
Ph phase_2
5
56%

Phase Distribution

2

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 25 (55.6%)
Phase 31 (11.1%)
Phase 41 (11.1%)

Trials by Status

terminated111%
completed889%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_1

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

NCT04410874
completedphase_4

Special Access Program IMVAMUNE®

NCT03472014
completedphase_2

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
completedphase_2

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

NCT00686582
completedphase_2

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

NCT00857493
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04410874Phase 1

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

Terminated
NCT03472014Phase 4

Special Access Program IMVAMUNE®

Completed
NCT02038881Phase 2

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Completed
NCT00686582Phase 2

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Completed
NCT00857493Phase 2

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Completed
NCT00316602Phase 2

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Completed
NCT01144637Phase 3

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Completed
NCT00189930Phase 2

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

Completed
NCT00390078Phase 1

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9